Bullous pemphigoid (BP), which has no FDA-approved ... with no relapse, and standard treatment with oral corticosteroids had been tailed off without the need for any rescue therapy.

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition ... with no relapse, and standard treatment with oral corticosteroids had been tailed off without the need for any ...

Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US ...

“People with bullous pemphigoid live with unrelenting itch, blisters and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can ...

This limited series explores both the physical and emotional impact of skin conditions with dermatologist Dr. Lindsay ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...